The observed expression of PD-1 and SIRPα by innate immune cells responding to and interacting with CNS lymphoma cells in vivo indicates that their anti-tumoral effect is partially impaired but also opens the opportunity to potentially target these cells by immunotherapies that aim at potentiating the autologous anti-tumoral immune response. Here, SIRPA is linked to primary central nervous system lymphoma.